

D1
122. (Amended) The recombinant RSV of claim 63, formulated in a dose of 10^3 to 10^6 PFU of attenuated virus.

D2
128. (Amended) An immunogenic composition effective to elicit an immune response in a mammalian subject directed against RSV, which comprises an immunologically sufficient amount of the recombinant RSV of claim 63 in a physiologically acceptable carrier.

D3
129. (Amended) The immunogenic composition of claim 128, formulated in a dose of 10^3 to 10^6 PFU of the attenuated RSV.

130. (Amended) The immunogenic composition of claim 128, formulated for administration to the upper respiratory tract by spray, droplet or aerosol.

D4
131. (Amended) The immunogenic composition of claim 128, wherein the recombinant RSV elicits an immune response against human RSV A, human RSV B, or both.